Singapore biotech firm Mirxes joins Hong Kong's Hang Seng Composite Index
In a StraitsTimes interview, Ooi Chee Keong, Partner and Head of Capital Markets, highlighted that Mirxes' entry into the index is a strategic move not only to elevate its visibility and credibility, but also allows access to global capital critical for scaling.
A strategic move for international exposure
Singapore biotech company Mirxes is making waves on the global stage with its recent inclusion in Hong Kong’s Hang Seng Composite Index (HSCI)—a move expected to boost its market profile and trading liquidity. This underscores a significant development for Singapore’s biotech sector, signalling increased opportunities for international exposure and investment.
“International exposure is essential. Being listed, whether on the Singapore Exchange (SGX), the Hong Kong Stock Exchange or Nasdaq, opens the door to institutional investors from funds to pension schemes and sovereign wealth funds, many of which can invest only in listed equities,” he said.
Aside from the bourse providing access to a market with nearly 30 times the daily trading volume in comparison to SGX, he added, "The Hong Kong Stock Exchange has also cultivated a specialised ecosystem for life sciences through its Chapter 18A listing rules, which cater specifically to pre-revenue biotech firms."
Read more on his insights about Mirxes' strategic listing and its impact on The Straits Times
How we can help
Navigating cross-border listings, biotech financing and international exposure requires specialised capital markets expertise. Get in touch with our capital markets team to discuss how we can support your growth and global expansion.
Our expert